BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taxus Express paclitaxel-eluting stent system: Phase III data

The trial originally enrolled 3,602 patients and also evaluated Angiomax bivalirudin vs. heparin plus a platelet GPIIb/IIIa inhibitor. The Medicines Co. (NASDAQ:MDCO, Parsippany, N.J.) markets Angiomax for multiple cardiovascular indications. Boston Scientific licensed rights to use paclitaxel in stents from Angiotech in 1997 (see BioCentury, July 14, 1997).

Angiotech...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >